These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial. Leth S; Schleimann MH; Nissen SK; Højen JF; Olesen R; Graversen ME; Jørgensen S; Kjær AS; Denton PW; Mørk A; Sommerfelt MA; Krogsgaard K; Østergaard L; Rasmussen TA; Tolstrup M; Søgaard OS Lancet HIV; 2016 Oct; 3(10):e463-72. PubMed ID: 27658863 [TBL] [Abstract][Full Text] [Related]
3. In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection. Tsai P; Wu G; Baker CE; Thayer WO; Spagnuolo RA; Sanchez R; Barrett S; Howell B; Margolis D; Hazuda DJ; Archin NM; Garcia JV Retrovirology; 2016 May; 13(1):36. PubMed ID: 27206407 [TBL] [Abstract][Full Text] [Related]
4. Relationship between Measures of HIV Reactivation and Decline of the Latent Reservoir under Latency-Reversing Agents. Petravic J; Rasmussen TA; Lewin SR; Kent SJ; Davenport MP J Virol; 2017 May; 91(9):. PubMed ID: 28202759 [TBL] [Abstract][Full Text] [Related]
5. Heterogeneous HIV-1 Reactivation Patterns of Disulfiram and Combined Disulfiram+Romidepsin Treatments. Kula A; Delacourt N; Bouchat S; Darcis G; Avettand-Fenoel V; Verdikt R; Corazza F; Necsoi C; Vanhulle C; Bendoumou M; Burny A; De Wit S; Rouzioux C; Rohr O; Van Lint C J Acquir Immune Defic Syndr; 2019 Apr; 80(5):605-613. PubMed ID: 30768485 [TBL] [Abstract][Full Text] [Related]
6. Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs. Tapia G; Højen JF; Ökvist M; Olesen R; Leth S; Nissen SK; VanBelzen DJ; O'Doherty U; Mørk A; Krogsgaard K; Søgaard OS; Østergaard L; Tolstrup M; Pantaleo G; Sommerfelt MA J Infect; 2017 Dec; 75(6):555-571. PubMed ID: 28917661 [TBL] [Abstract][Full Text] [Related]
7. Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapy. Elliott JH; Wightman F; Solomon A; Ghneim K; Ahlers J; Cameron MJ; Smith MZ; Spelman T; McMahon J; Velayudham P; Brown G; Roney J; Watson J; Prince MH; Hoy JF; Chomont N; Fromentin R; Procopio FA; Zeidan J; Palmer S; Odevall L; Johnstone RW; Martin BP; Sinclair E; Deeks SG; Hazuda DJ; Cameron PU; Sékaly RP; Lewin SR PLoS Pathog; 2014 Oct; 10(10):e1004473. PubMed ID: 25393648 [TBL] [Abstract][Full Text] [Related]
8. Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4(+) T Cells from Aviremic Patients. Spivak AM; Bosque A; Balch AH; Smyth D; Martins L; Planelles V Antimicrob Agents Chemother; 2015 Oct; 59(10):5984-91. PubMed ID: 26169416 [TBL] [Abstract][Full Text] [Related]
9. HIVconsv Vaccines and Romidepsin in Early-Treated HIV-1-Infected Individuals: Safety, Immunogenicity and Effect on the Viral Reservoir (Study BCN02). Mothe B; Rosás-Umbert M; Coll P; Manzardo C; Puertas MC; Morón-López S; Llano A; Miranda C; Cedeño S; López M; Alarcón-Soto Y; Melis GG; Langohr K; Barriocanal AM; Toro J; Ruiz I; Rovira C; Carrillo A; Meulbroek M; Crook A; Wee EG; Miró JM; Clotet B; Valle M; Martinez-Picado J; Hanke T; Brander C; Moltó J; Front Immunol; 2020; 11():823. PubMed ID: 32435247 [TBL] [Abstract][Full Text] [Related]
10. Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations. Winckelmann A; Barton K; Hiener B; Schlub TE; Shao W; Rasmussen TA; Østergaard L; Søgaard OS; Tolstrup M; Palmer S AIDS; 2017 Mar; 31(6):771-779. PubMed ID: 28272134 [TBL] [Abstract][Full Text] [Related]
11. Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals. Moron-Lopez S; Kim P; Søgaard OS; Tolstrup M; Wong JK; Yukl SA AIDS; 2019 Mar; 33(3):425-431. PubMed ID: 30531314 [TBL] [Abstract][Full Text] [Related]
12. Rosás-Umbert M; Ruiz-Riol M; Fernández MA; Marszalek M; Coll P; Manzardo C; Cedeño S; Miró JM; Clotet B; Hanke T; Moltó J; Mothe B; Brander C; Front Immunol; 2020; 11():418. PubMed ID: 32265913 [TBL] [Abstract][Full Text] [Related]
13. Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. Wei DG; Chiang V; Fyne E; Balakrishnan M; Barnes T; Graupe M; Hesselgesser J; Irrinki A; Murry JP; Stepan G; Stray KM; Tsai A; Yu H; Spindler J; Kearney M; Spina CA; McMahon D; Lalezari J; Sloan D; Mellors J; Geleziunas R; Cihlar T PLoS Pathog; 2014 Apr; 10(4):e1004071. PubMed ID: 24722454 [TBL] [Abstract][Full Text] [Related]
14. Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy. Archin NM; Liberty AL; Kashuba AD; Choudhary SK; Kuruc JD; Crooks AM; Parker DC; Anderson EM; Kearney MF; Strain MC; Richman DD; Hudgens MG; Bosch RJ; Coffin JM; Eron JJ; Hazuda DJ; Margolis DM Nature; 2012 Jul; 487(7408):482-5. PubMed ID: 22837004 [TBL] [Abstract][Full Text] [Related]
15. Effect of 3BNC117 and romidepsin on the HIV-1 reservoir in people taking suppressive antiretroviral therapy (ROADMAP): a randomised, open-label, phase 2A trial. Gruell H; Gunst JD; Cohen YZ; Pahus MH; Malin JJ; Platten M; Millard KG; Tolstrup M; Jones RB; Conce Alberto WD; Lorenzi JCC; Oliveira TY; Kümmerle T; Suárez I; Unson-O'Brien C; Nogueira L; Olesen R; Østergaard L; Nielsen H; Lehmann C; Nussenzweig MC; Fätkenheuer G; Klein F; Caskey M; Søgaard OS Lancet Microbe; 2022 Mar; 3(3):e203-e214. PubMed ID: 35544074 [TBL] [Abstract][Full Text] [Related]
16. In Vitro Reactivation of Replication-Competent and Infectious HIV-1 by Histone Deacetylase Inhibitors. Banga R; Procopio FA; Cavassini M; Perreau M J Virol; 2016 Feb; 90(4):1858-71. PubMed ID: 26656693 [TBL] [Abstract][Full Text] [Related]